

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-13. (Canceled)

14. (Currently Amended) A method of inhibiting a body weight gain in a mammal, which comprises administering an effective amount of a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof and an effective amount of a PPAR γ agonist-like substance in combination, to the mammal, wherein the body weight gain is induced by a PPAR γ agonist-like substance.

15. (Canceled)

16. (Canceled)

17. (Previously Presented) The method according to claim 14, wherein the compound having an angiotensin II antagonistic activity is 2-ethoxy-1-[[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid.

18. (Canceled)

19. (Previously Presented) The method according to claim 14, wherein the PPAR γ agonist-like substance is pioglitazone.

20. (Previously Presented) The method according to claim 14, wherein the body weight gain occurs before reaching obesity.

21. (Canceled)

22. (Canceled)

23. (New) A method of inhibiting a body weight gain in a mammal comprising administering a composition consisting of an effective amount of 2-ethoxy-1-[[2'-(5-oxo-

2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, a prodrug thereof or a salt thereof, an effective amount of a PPAR γ agonist, and a pharmaceutically acceptable carrier in combination to the mammal.

24. (New) The method of claim 23 wherein the PPAR γ agonist is pioglitazone.